» Articles » PMID: 39596984

Evaluating Severe Therapy-Resistant Asthma in Children: Diagnostic and Therapeutic Strategies

Overview
Publisher MDPI
Specialty General Medicine
Date 2024 Nov 27
PMID 39596984
Authors
Affiliations
Soon will be listed here.
Abstract

: Worldwide, asthma is the most common non-communicable respiratory disease and causes considerable morbidity and mortality. Most people with asthma can be treated effectively with low-dose medications if these are taken correctly and regularly. Around 10% of people with asthma have an uncontrolled form of the disease or can only achieve control with high-dose medications, incurring disproportionately high health care costs. : PubMed and personal archives were searched for relevant articles on the definition, management and pharmacotherapy of severe asthma. The WHO classification of severe asthma and the treatment levels encompassed in the definition are discussed. Most children and young people referred for consideration of 'beyond-guidelines therapy' can in fact be managed on standard treatment after a multi-disciplinary team assessment focusing on ensuring correct basic management, and these steps are described in detail. Options for those with true therapy-resistant asthma are described. These include monoclonal antibodies, most of which target type 2 inflammation. : Getting the basics right is still the most important aspect of asthma care. For those with severe, therapy-resistant asthma, an increasing number of life-transforming monoclonals have been developed, but there is still little understanding of, and a paucity of treatment options for, non-eosinophilic asthma.

Citing Articles

Retrospective Study of the Impact of SARS-CoV-2 Infection on Asthma Control in Children.

Abdul-Razzak J, Ionescu M, Diaconu R, Popescu A, Niculescu E, Gafencu M J Clin Med. 2025; 14(2).

PMID: 39860362 PMC: 11766123. DOI: 10.3390/jcm14020356.

References
1.
Nagakumar P, Gambir N, Sanghani N, Hall P, Jamalzadeh A, Beresford F . Role of a prolonged inpatient admission when evaluating children with problematic severe asthma. Eur Respir J. 2018; 51(2). DOI: 10.1183/13993003.01061-2017. View

2.
Lodrup Carlsen K, Hedlin G, Bush A, Wennergren G, De Benedictis F, de Jongste J . Assessment of problematic severe asthma in children. Eur Respir J. 2010; 37(2):432-40. DOI: 10.1183/09031936.00091410. View

3.
Hartl S, Breyer M, Burghuber O, Ofenheimer A, Schrott A, Urban M . Blood eosinophil count in the general population: typical values and potential confounders. Eur Respir J. 2020; 55(5). DOI: 10.1183/13993003.01874-2019. View

4.
Peters-Golden M, Swern A, Bird S, Hustad C, Grant E, Edelman J . Influence of body mass index on the response to asthma controller agents. Eur Respir J. 2006; 27(3):495-503. DOI: 10.1183/09031936.06.00077205. View

5.
Zar H, Streun S, Levin M, Weinberg E, Swingler G . Randomised controlled trial of the efficacy of a metered dose inhaler with bottle spacer for bronchodilator treatment in acute lower airway obstruction. Arch Dis Child. 2006; 92(2):142-6. PMC: 2083341. DOI: 10.1136/adc.2006.101642. View